NCT01100996

Brief Summary

During sepsis and septic shock the immune response can be overwhelming leading to excessive tissue damage, organ failure and death. Ideally, the inflammatory response is modulated leading to both adequate protection to invading pathogens as well as limitation of an exuberant immune response. In the last years, experimental evidence has been accumulating that enteral administration of lipid-enriched nutrition attenuates inflammation and preserves organ integrity in several inflammatory models. The current study investigates the immune-modulating potential of enriched enteral nutrition in a human setting of experimental endotoxemia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
36

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2010

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2010

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

April 7, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 9, 2010

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2011

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2011

Completed
Last Updated

June 7, 2011

Status Verified

February 1, 2010

Enrollment Period

1.1 years

First QC Date

April 7, 2010

Last Update Submit

June 6, 2011

Conditions

Keywords

enteral nutritionendotoxemiainnate immunitynutritional anti-inflammatory pathwayintestinal damage

Outcome Measures

Primary Outcomes (1)

  • circulating cytokines

    several time points from LPS administration until 24 hours

Secondary Outcomes (1)

  • markers for sub-clinical organ damage (kidney, endothelium, intestine)

    several time points from LPS administration until 24 h

Study Arms (3)

fasted control

NO INTERVENTION

Volunteers are fasted for 10 hours and subjected to experimental endotoxemia

control feeding

PLACEBO COMPARATOR

Volunteers are fed a control nutrition starting 1 hour prior to LPS administration until 6 hours after LPS

Other: control enteral nutrition

enriched feeding

ACTIVE COMPARATOR

volunteers receive the investigational feeding starting 1 hour prior to LPS administration until 6 hours after LPS

Other: enriched enteral feeding

Interventions

This feeding consists of 20en% fat, 16en% protein and 49en% carbohydrates

control feeding

This feeding contains 46 energy percent (en%) fat, 24en% protein and 30en% carbohydrates and is enriched with phospholipids.

enriched feeding

Eligibility Criteria

Age18 Years - 35 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Age ≥ 18 and ≤ 35 yrs
  • Male
  • Written informed consent
  • non-smoking

You may not qualify if:

  • Use of any medication (e.g. NSAID's, antibiotics, gastrointestinal motility altering medicine, corticosteroids)
  • Smoking in the past year
  • History, signs or symptoms of cardiovascular disease
  • (Family; first degree) history of cerebrovascular disease
  • Previous vagal collapse
  • Hypertension (defined as RR systolic \> 160 or RR diastolic \> 90)
  • Hypotension (defined as RR systolic \< 100 or RR diastolic \< 50)
  • Renal impairment (defined as plasma creatinin \>120 μmol/l)
  • Liver enzyme abnormalities ( ASAT \> 60 U/L, ALAT \> 75 U/L, Gamma-GT \> 60 U/L)
  • Positive hepatitis serology
  • Positive HIV test
  • Allergy to milk and/or soy proteins

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Radboud University Medical Center

Nijmegen, 6525 GA, Netherlands

Location

Related Publications (4)

  • Luyer MD, Greve JW, Hadfoune M, Jacobs JA, Dejong CH, Buurman WA. Nutritional stimulation of cholecystokinin receptors inhibits inflammation via the vagus nerve. J Exp Med. 2005 Oct 17;202(8):1023-9. doi: 10.1084/jem.20042397. Epub 2005 Oct 10.

    PMID: 16216887BACKGROUND
  • Luyer MD, Derikx JP, Beyaert R, Hadfoune M, van Kuppevelt TH, Dejong CH, Heineman E, Buurman WA, Greve JW. High-fat nutrition reduces hepatic damage following exposure to bacterial DNA and hemorrhagic shock. J Hepatol. 2009 Feb;50(2):342-50. doi: 10.1016/j.jhep.2008.08.025. Epub 2008 Nov 8.

    PMID: 19070388BACKGROUND
  • de Haan JJ, Lubbers T, Hadfoune M, Luyer MD, Dejong CH, Buurman WA, Greve JW. Postshock intervention with high-lipid enteral nutrition reduces inflammation and tissue damage. Ann Surg. 2008 Nov;248(5):842-8. doi: 10.1097/SLA.0b013e318188752c.

    PMID: 18948813BACKGROUND
  • Lubbers T, Luyer MD, de Haan JJ, Hadfoune M, Buurman WA, Greve JW. Lipid-rich enteral nutrition reduces postoperative ileus in rats via activation of cholecystokinin-receptors. Ann Surg. 2009 Mar;249(3):481-7. doi: 10.1097/SLA.0b013e318194d187.

    PMID: 19247038BACKGROUND

MeSH Terms

Conditions

Endotoxemia

Condition Hierarchy (Ancestors)

BacteremiaSepsisInfectionsToxemiaSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Johannes Van der Hoeven, PhD, MD

    Department of Intensive Care Medicine, Radboud University Nijmegen Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 7, 2010

First Posted

April 9, 2010

Study Start

February 1, 2010

Primary Completion

March 1, 2011

Study Completion

April 1, 2011

Last Updated

June 7, 2011

Record last verified: 2010-02

Locations